Detalhe da pesquisa
1.
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
Cancer
; 130(8): 1270-1280, 2024 Apr 15.
Artigo
Inglês
| MEDLINE | ID: mdl-38153814
2.
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
Ann Hematol
; 103(2): 427-436, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38012435
3.
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.
Ann Hematol
; 103(2): 437-442, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38060001
4.
Newly identified roles for PIEZO1 mechanosensor in controlling normal megakaryocyte development and in primary myelofibrosis.
Am J Hematol
; 99(3): 336-349, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-38165047
5.
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
Cancer
; 129(11): 1704-1713, 2023 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36932983
6.
Trend of circulating CD34+ cells in patients with myelofibrosis: Association with spleen response during ruxolitinib treatment.
Br J Haematol
; 200(3): 315-322, 2023 02.
Artigo
Inglês
| MEDLINE | ID: mdl-36266779
7.
Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort.
Ann Hematol
; 102(6): 1409-1420, 2023 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-37079068
8.
Essential Thrombocythemia in Adolescents and Young Adults: Clinical Aspects, Treatment Options and Unmet Medical Needs.
Curr Treat Options Oncol
; 24(7): 802-820, 2023 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-37195587
9.
Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Clinical Relevance, Impact on Outcome, Preventive Measures and Treatment Strategies.
Curr Treat Options Oncol
; 24(12): 1720-1738, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-38047977
10.
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study.
Br J Haematol
; 197(2): 190-200, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35137397
11.
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms.
Blood
; 135(2): 133-144, 2020 01 09.
Artigo
Inglês
| MEDLINE | ID: mdl-31697806
12.
A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia.
Blood
; 136(2): 171-182, 2020 07 09.
Artigo
Inglês
| MEDLINE | ID: mdl-32266380
13.
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study.
Blood
; 135(5): 381-386, 2020 01 30.
Artigo
Inglês
| MEDLINE | ID: mdl-31869407
14.
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome.
Cancer
; 127(15): 2657-2665, 2021 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33794557
15.
Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
Br J Haematol
; 193(2): 356-368, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33222197
16.
Cytogenetic study in primary myelofibrosis at diagnosis: Clinical and histological association and impact on survival according to WHO 2017 classification in an Italian multicenter series.
Hematol Oncol
; 39(1): 123-128, 2021 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-32979286
17.
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors.
Hematol Oncol
; 39(3): 401-408, 2021 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-33617659
18.
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib.
Ann Hematol
; 100(8): 2005-2014, 2021 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-33388860
19.
Vehicle Localization Using 3D Building Models and Point Cloud Matching.
Sensors (Basel)
; 21(16)2021 Aug 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34450798
20.
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.
Cancer
; 126(6): 1243-1252, 2020 03 15.
Artigo
Inglês
| MEDLINE | ID: mdl-31860137